The global single use bioprocess market is on a robust growth trajectory, expected to surge from USD 17.7 billion in 2024 to USD 34.9 billion by 2029, reflecting a strong CAGR of 14.5%. This dynamic shift isn’t just a trend—it’s a strategic transformation impacting contract development and manufacturing organizations (CDMOs), contract manufacturing organizations (CMOs), and pharmaceutical innovators alike. But why are single use solutions becoming the go-to choice in modern biomanufacturing?

For C-level executives in biotech and pharma, understanding the operational, financial, and environmental implications of this transformation is crucial for aligning investments with emerging best practices and ensuring long-term ROI.

What Are Single Use Bioprocess Solutions?

Single use bioprocessing refers to the implementation of disposable technologies—such as single use bioreactors, filtration assemblies, tubing, connectors, and bags—within upstream and downstream biomanufacturing workflows. These components are designed for one-time use and are typically composed of plastic polymers.

Unlike traditional stainless-steel systems, which require intensive cleaning and validation, disposable bioreactor systems and associated components eliminate cleaning needs, reduce contamination risks, and streamline operations.
Download PDF Brochure: 

Why Are Executives Turning to Single Use Bioprocess Technologies?

1. Enhanced Operational Efficiency

The use of single use bioreactors significantly reduces turnaround times between batches, improving facility throughput. This rapid scale-up capability is vital for CDMOs and biopharma firms managing multiple client projects or product lines.

2. Cost Efficiency and Capital Preservation

By eliminating the need for costly stainless-steel infrastructure, utilities for cleaning, and labor-intensive validation processes, single use solutions offer a lower barrier to entry and enable CAPEX optimization. These systems are especially beneficial for small and mid-sized biopharma companies operating under tight budgets.

3. Reduced Risk of Cross-Contamination

With pre-sterilized, disposable systems, the risk of contamination is significantly minimized. This is particularly important in multiproduct facilities where cross-contamination can lead to costly delays or regulatory non-compliance.

4. Sustainability Gains

Single use systems help companies meet sustainability goals by reducing water and energy usage typically consumed during CIP (clean-in-place) and SIP (sterilize-in-place) procedures. This aligns with growing ESG commitments and investor expectations.

Who Is Leading the Single Use Bioprocess Market?

The market landscape is both competitive and innovation-driven, with leading players investing heavily in portfolio expansion and global outreach.

Merck KGaA (Germany)

A key player offering a broad range of single use bioprocess products. With robust R&D capabilities and strategic regional expansions, Merck continues to strengthen its position by meeting the evolving demands of end-users globally.

Danaher Corporation (US)

Post its acquisition of Pall Corporation, Danaher has become a dominant force in the market. It boasts a powerful line-up of single use bioreactor systems, filtration solutions, and consumables. Recent acquisitions and strategic collaborations across China, France, and the US have helped consolidate its market share.

Sartorius AG (Germany)

Known for its innovation in single use solutions, Sartorius has developed advanced products like Sartolab RF|BT for enhanced vacuum filtration. Their high R&D investment and strategic expansions have positioned them as a preferred partner for CROs, CDMOs, and pharmaceutical giants.

What Challenges Threaten Market Expansion?

Despite the impressive growth outlook, several headwinds could limit market scalability:

• Leachables and Extractables: Chemical contaminants leaching from plastic components can affect product safety and efficacy.
• Regulatory Scrutiny: Compliance with evolving FDA and EMA standards for single use components remains complex.
• PFAS Restrictions: Increasing regulation of per- and polyfluoroalkyl substances (PFAS), used in certain bioprocessing films and coatings, may require reengineering of key components.

Forward-thinking companies are addressing these issues by investing in safer materials, conducting extensive validation studies, and engaging early with regulators.

When Should Biopharma Companies Make the Switch?

The best time to integrate disposable bioreactors and single use systems is during early facility planning or when undergoing capacity expansions. Retrofitting existing stainless-steel setups can be more complex and less cost-effective. However, for new market entrants or companies transitioning to modular, flexible facilities, the shift to single use is a strategic imperative.

Where Is the Market Headed?

Looking forward, adoption is expected to intensify in:

• Emerging markets like Asia-Pacific, driven by biologics demand and favorable government policies.
• Cell and gene therapy sectors, which benefit from small-batch, high-purity manufacturing.
• Modular facility designs, enabling scalable and relocatable operations.

The market’s top four companies—Sartorius AG, Danaher Corporation, Thermo Fisher Scientific, and Merck KGaA—currently control 44–48% of global market share, setting the pace in product innovation and commercialization strategies.

How Can Executives Maximize ROI from Single Use Technologies?

To capitalize on the single use trend, C-level leaders should:

• Partner with flexible and innovative suppliers offering scalable product portfolios.
• Invest in workforce training to manage new technologies effectively.
• Incorporate digital monitoring tools to track performance and preempt failures.
• Conduct full lifecycle cost analysis, including waste management and environmental impact.

Conclusion

The shift to single use bioprocess technologies is no longer a futuristic concept—it’s the new normal for agile, scalable, and sustainable biomanufacturing. For executive teams in pharma and biotech, embracing single use solutions is key to achieving operational excellence, regulatory compliance, and competitive differentiation.

By investing in single use bioreactors and disposable bioreactor systems, companies can reduce time-to-market, lower capital costs, and build resilient supply chains fit for the future of medicine.

For More information, Inquire Now.